上海，2026年5月18日 - 藥明康德近日宣布公司入選2026道瓊斯領(lǐng)先全球指數(shù)（Dow Jones Best-in-Class World Index，原道瓊斯可持續(xù)發(fā)展世界指數(shù)），該指數(shù)基于企業(yè)長(zhǎng)期可持續(xù)發(fā)展標(biāo)準(zhǔn)，評(píng)選出全球各行業(yè)處于領(lǐng)先水平的公司。這一認(rèn)可充分彰顯了公司在推動(dòng)可持續(xù)發(fā)展和踐行負(fù)責(zé)任商業(yè)實(shí)踐方面的堅(jiān)定承諾。

道瓊斯領(lǐng)先全球指數(shù)由標(biāo)普全球通過(guò)企業(yè)可持續(xù)發(fā)展評(píng)估（CSA）進(jìn)行評(píng)選。該評(píng)估體系采用行業(yè)特定視角，重點(diǎn)關(guān)注對(duì)長(zhǎng)期發(fā)展具有實(shí)質(zhì)性影響的經(jīng)濟(jì)、環(huán)境和社會(huì)議題。該指數(shù)僅納入在各自領(lǐng)域排名前列的企業(yè)。

“很榮幸入選道瓊斯領(lǐng)先全球指數(shù)，這體現(xiàn)了藥明康德將可持續(xù)發(fā)展深度融入企業(yè)戰(zhàn)略和日常運(yùn)營(yíng)的不懈努力。”藥明康德聯(lián)席首席執(zhí)行官兼可持續(xù)發(fā)展委員會(huì)主席楊青博士表示：“我們將持續(xù)加強(qiáng)全球化能力建設(shè)和產(chǎn)能投放，與行業(yè)同仁攜手共建更健康、更可持續(xù)的未來(lái)，早日實(shí)現(xiàn)‘讓天下沒(méi)有難做的藥，難治的病’的偉大愿景。”

作為創(chuàng)新的賦能者、客戶信賴的合作伙伴以及全球健康產(chǎn)業(yè)的貢獻(xiàn)者，藥明康德和大多數(shù)客戶一樣，積極踐行對(duì)可持續(xù)發(fā)展的承諾。截至目前，公司連續(xù)五年獲得MSCI ESG領(lǐng)導(dǎo)力評(píng)級(jí)，并在最新的評(píng)估中首次獲得“AAA”最高評(píng)級(jí)；連續(xù)四年入選標(biāo)普全球《可持續(xù)發(fā)展年鑒》；連續(xù)三年入選富時(shí)羅素社會(huì)責(zé)任指數(shù)系列；連續(xù)兩年獲得EcoVadis企業(yè)社會(huì)責(zé)任評(píng)級(jí)“金牌”認(rèn)證；連續(xù)兩年獲得CDP水安全最高評(píng)級(jí)“A”級(jí)，并首次獲得CDP氣候變化最高評(píng)級(jí)“A”級(jí)；連續(xù)兩年在ISS ESG企業(yè)評(píng)級(jí)中獲得“Prime”表彰。

此外，為進(jìn)一步深化可持續(xù)發(fā)展承諾，藥明康德持續(xù)拓展全球責(zé)任實(shí)踐。公司溫室氣體減排近期目標(biāo)成功通過(guò)了SBTi審核認(rèn)證。同時(shí)，公司已加入聯(lián)合國(guó)全球契約組織（UNGC），承諾支持全球契約十項(xiàng)原則；并加入制藥供應(yīng)鏈倡議（PSCI），成為PSCI供應(yīng)商合作伙伴。

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學(xué)行業(yè)值得信賴的合作伙伴和重要貢獻(xiàn)者，致力于通過(guò)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，推動(dòng)全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地，依托獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來(lái)突破性的治療方案。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家的合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒(méi)有難做的藥，難治的病”的愿景。更多信息，請(qǐng)?jiān)L問(wèn)公司網(wǎng)站：www.wuxiapptec.com

WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

SHANGHAI, May 17, 2026 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), which recognizes the top-performing companies in each industry on long-term sustainability criteria. This recognition reflects progress that WuXi AppTec has made in integrating responsible sustainability practices across its operations and strategies.

The Dow Jones Best-in-Class World Index, administered by S&P Global through its Corporate Sustainability Assessment (CSA), selects companies that rank in the top tier of their respective industries on long-term economic, environmental, and social criteria. The CSA evaluates companies through the lens of their specific industries, weighting sustainability factors by their relevance to long-term performance. Index inclusion is reserved for companies that rank in the top tier of their sector.

“We are honored to be included on the Dow Jones Best-in-Class World Index, which reflects WuXi AppTec’s continued efforts to embed sustainability into our corporate strategy and daily operations,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “We will continue to strengthen our global capabilities and capacity as a trusted partner to the global pharmaceutical industry, and to build a world where ‘every drug can be made, and every disease can be treated.’”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s sustainability performance has received top-tier ratings across every major independent ESG framework:

• Has received the MSCI ESG leadership rating for five consecutive years, achieving its first “AAA” rating in the most recent assessment.

• Has been included in the S&P Global Sustainability Yearbook for four consecutive years.

• Has been listed in the FTSE4Good Index Series for three consecutive years.

• Has been awarded a “Gold” medal in sustainability by EcoVadis for the second consecutive year.

• Has maintained the highest “A” rating in CDP Water Security for two consecutive years and achieved the highest “A” rating in CDP Climate Change for the first time.

• Has been awarded “Prime” Status in the ISS ESG Corporate Rating for two consecutive years.

Furthering its sustainability commitments, WuXi AppTec’s near-term greenhouse gas emissions reduction targets have been validated by the Science Based Targets initiative (SBTi). The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場(chǎng)，亦不代表藥明康德支持或反對(duì)文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請(qǐng)前往正規(guī)醫(yī)院就診。

版權(quán)說(shuō)明：歡迎個(gè)人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺(tái)。轉(zhuǎn)載授權(quán)請(qǐng)?jiān)凇杆幟骺档隆刮⑿殴娞?hào)回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。